Enveric Biosciences Inc Stock Price, News & Analysis

Enveric Biosciences (NASDAQ: ENVB) has announced strategic updates through a CEO letter to shareholders. The company has repositioned to focus on developing EB-003, their lead non-hallucinogenic neuroplastogenic drug candidate for anxiety, depression, and addiction disorders. Recent data shows EB-003's ability to bind to the 5-HT2A receptor and induce neuroplasticity without significant hallucinatory effects.

The company completed several licensing agreements in 2024-2025, including partnerships with Aries Science & Technology, MycoMedica Life Sciences, and Restoration Biologics. Enveric recently secured new U.S. patents for their EVM301 series and unveiled the EVM401 Series of mescaline-inspired drug candidates.

Financially, Enveric completed a public offering raising approximately $5 million in gross proceeds after implementing a reverse stock split. The company is now preparing for EB-003's Investigational New Drug (IND) application and subsequent Phase 1 clinical trials.

Enveric Biosciences (NASDAQ: ENVB) has secured U.S. Patent No. 12,195,439 for its new EVM401 Series of mescaline derivative compounds. The patent, issued on January 14, 2025, covers 'Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives.'

Preliminary testing shows these compounds demonstrate unique brain receptor modulation patterns, potentially interacting with:

• α2A adrenergic receptor (ADRA2A) - helpful for opioid withdrawal and ADHD
• 5-HT2C receptor - target for neuropsychiatric diseases, substance use disorders, anxiety and depression
• Dopamine transporter (DAT) - important for substance use disorder treatment

While the company's main focus remains on the IND application for EB-003, this patent aims to expand their pipeline of non-hallucinogenic molecules for treating addiction and neuropsychiatric disorders.

Enveric Biosciences (NASDAQ: ENVB) has announced that its subsidiary, Akos Biosciences, has entered into two licensing agreements with Restoration Biologics for cannabinoid-COX-2 conjugate compounds. The agreements cover both pharmaceutical and non-pharmaceutical applications for human and animal use, primarily focusing on joint pathologies like osteoarthritis and rheumatoid arthritis.

The exclusive, global licenses grant Restoration Biologics full development, marketing, and commercialization rights. The agreements include potential milestone payments totaling $61 million for the pharmaceutical license and $21 million for the non-pharmaceutical license. Royalty rates range from low single digit to low double digits on future sales, contingent on meeting specific sales criteria.

Enveric Biosciences (NASDAQ: ENVB) has completed its previously announced public offering, raising $5 million in gross proceeds. The offering consisted of 1,666,666 shares of common stock (or equivalents) and two series of warrants at a combined price of $3.00 per share.

The offering included Series A warrants expiring in five years and Series B warrants expiring in eighteen months, both with a $3.00 exercise price. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the proceeds for product development, working capital, and general corporate purposes.

The offering was conducted under a Form S-1 registration statement declared effective by the SEC on January 30, 2025.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics, has announced the pricing of a $5 million public offering. The offering includes 1,666,666 shares of common stock (or equivalents) with Series A and Series B warrants, priced at $3.00 per share.

Each share comes with one Series A warrant (5-year expiration) and one Series B warrant (18-month expiration), both with a $3.00 exercise price. The offering is expected to close around February 3, 2025, with H.C. Wainwright & Co. acting as exclusive placement agent. The company plans to use the proceeds for product development, working capital, and general corporate purposes.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for anxiety, depression, and addiction disorders, has announced its participation in two major industry events during 'J.P. Morgan Week 2025' in San Francisco.

CEO Joseph Tucker, Ph.D., will participate in a panel discussion on 'Future of Psychedelics' and deliver a presentation at the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025. The panel discussion is scheduled for 2:20 p.m. PDT, followed by the presentation at 4:05 p.m. PDT at the Marines' Memorial Club.

Additionally, the company will attend Biotech Showcase 2025 from January 13-15, 2025, at the Hilton San Francisco Union Square. During both events, Enveric's management team will conduct one-on-one meetings with registered investors and potential partners to discuss their business strategy, recent achievements, and upcoming milestones.

Sinclair has announced that 'The Triple Option' podcast will broadcast live from the Army-Navy Game Media Row presented by USAA on December 13, 2024, from 12-1:30pm ET. The special broadcast, hosted by Urban Meyer, Mark Ingram II, and Rob Stone, will take place at the Military Women's Memorial in Arlington National Cemetery. USAA CEO Wayne Peacock will be a featured guest on the show.

The live broadcast will be available on the podcast's YouTube, X, and Facebook platforms (@3xoptionshow), with an on-demand version available later. USAA will maintain a strong presence across Sinclair's owned/operated station websites throughout December, with the partnership developed in collaboration with Publicis Lion Company.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic therapeutics, announced the issuance of two U.S. patents (Nos. 12,133,856 and 12,138,276) for its EVM301 series molecules, bringing the total to 11 patents. These patents cover novel psilocybin derivative compounds and their pharmaceutical formulations. Enveric's lead candidate, EB-003, targets anxiety, depression, and addiction disorders, showing potential for promoting neuroplasticity without hallucinogenic effects. Additionally, two other patents (Nos. 12,065,404 and 12,077,498) were issued for EVM201 series prodrugs, protecting novel tryptamine derivatives. Enveric has licensed its EVM201 series to MycoMedica Life Sciences and announced out-licensing deals with MycoMedica and Aries Science & Technology, positioning Enveric to focus on EB-003 development and establish potential future income streams.

Enveric Biosciences (NASDAQ: ENVB) announced positive results from preclinical pharmacokinetic studies of EB-003, demonstrating favorable oral bioavailability and brain penetration without hallucination-like behavior in rat and dog models. The studies showed dose-proportional oral bioavailability and a significant brain/plasma ratio of 5-6 in rats, higher than previously observed in mice (~1.5). No clinical signs of hallucination were observed in either species. The company plans to submit an Investigational New Drug (IND) application to the FDA in the second half of 2025 for this potential treatment of depression, anxiety, and other psychiatric disorders.